Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotech Business
Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement
February 18th, 2009
Oxford Expression Technologies (OET), a leading provider of baculovirus-based protein expression products and services, and Eden Biodesign, an expert provider of biopharmaceutical process development and cGMP manufacturing services, have announced that they have signed a co-marketing agreement. Under the terms of the agreement, OET will offer its customers access to Eden Biodesign's process development, clinical trial cGMP manufacturing and analytical development services. In return, Eden Biodesign's customers will have access to OET's wide range of baculovirus capabilities to meet their individual protein expression requirements. OET customers will...
Source: Vaccine Weekly (2009-02-18)
|
